Publications
pharmacokinetics (55 POSTS)
2005 (3 POSTS)
Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding and uterine tissue dose metrics of bisphenol A: A physiologically based pharmacokinetic approach
Teeguarden JG, Waechter JM, Clewell HJ, Covington TR, Barton HA. Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding and uterine tissue dose metrics of bisphenol A: A physiologically based pharmacokinetic approach. Poster presented at Society of Toxicology 44th Annual Meeting, New Orleans, LA, March 2005.
2004 (1 POST)
Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry
Clewell HJ, Gentry PR, Covington TR, Sarangapani R, Teeguarden JG. 2004. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol Sci 79(2):381–93; doi: 10.1093/toxsci/kfh109.
View Abstract2003 (1 POST)
Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation
Gentry RP, Covington TR, Clewell HJ III. 2003. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul Toxicol Pharmacol 38(1):1–16; doi: 10.1016/S0273-2300(03)00047-3.
View Abstract2002 (1 POST)
Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences in tissue dosimetry
Gentry R, Teeguarden J, Sarangapani R, Covington T, Lawrence G, McDonald T, Shipp A, Clewell H. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences in tissue dosimetry. Poster presented at Society of Toxicology 41st Annual Meeting, Nashville, TN, March 2002.
2001 (2 POSTS)
Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry
Covington TR, Teeguarden J, Sarangapani R, Gentry PR, Clewell HJ. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Presentation at the Annual Society for Risk Analysis Conference, Seattle, WA, December 2001.
Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone
Clewell HJ, Gentry PR, Gearhart JM, Covington TR, Banton MI, Andersen ME. 2001. Development of a physiologically based pharmacokinetic model of isopropanol and its metabolite acetone. Toxicol Sci 63(2):160–172; doi: 10.1093/toxsci/63.2.160.
View Abstract2000 (3 POSTS)
Recombinant P450 2D18 metabolism of dopamine and arachidonic acid
Thompson CM, Capdevila JH, Strobel HW. 2000. Recombinant P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exper Ther 294(3):1120–1130; doi: 10.1016/S0022-3565(24)39180-3.
View AbstractDevelopment of a physiologically-based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment
Clewell HJ III, Gentry PR, Allen BC, Covington TR, Gearhart JM. 2000. Development of a physiologically-based pharmacokinetic model of trichloroethylene and its metabolites for use in risk assessment. Environ Health Perspect 108(Suppl 2):283–305; doi: 10.1289/ehp.00108s2283.
View AbstractDevelopment of a physiologically-based pharmacokinetic (PB-PK) model and human health risk assessment for coumarin
Clewell HJ, Gentry PR, Gearhart JM, Born SL, Lehman-McKeeman LD, Covington TR. Development of a physiologically-based pharmacokinetic (PB-PK) model and human health risk assessment for coumarin. Poster presented at Society of Toxicology 39th Annual Meeting, Philadelphia, PA, March 2000.
1999 (3 POSTS)
Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics
Clewell HJ, Gearhart JM, Gentry PR, Covington TR, Van Landingham CB, Crump KS, and Shipp AM. 1999. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal 19(4):541–552; doi: 10.1111/j.1539-6924.1999.tb00427.x.
View AbstractDeveloping a physiologically based pharmacokinetic model to describe methylene chloride kinetics at the subcellular level
Rish W, Kirman CR, Hays SM, Gargas ML, Andersen ME, Reitz RH, Guengerich FP, Green T, McConnell EE, Buckpit A, Voytek P, Dugard PH. 1999. Developing a physiologically based pharmacokinetic model to describe methylene chloride kinetics at the subcellular level. Toxicologist 48, Paper No. 671. Presented at Society of Toxicology 38th Annual Meeting, New Orleans, LA, March 1999.
Development of a physiologically-based pharmacokinetic (PB-PK) model for isopropanol and acetone
Gentry R, Clewell H, Gearhart J, Covington T, Andersen M. Development of a physiologically-based pharmacokinetic (PB-PK) model for isopropanol and acetone. Poster presented at Society of Toxicology 38th Annual Meeting, New Orleans, LA, March 1999.
1998 (1 POST)
Evaluation of the uncertainty in the RfD for methylmercury due to interindividual variability in pharmacokinetics
Van Landingham CB, Covington TR, Gearhart JM, Clewell HJ. Evaluation of the uncertainty in the RfD for methylmercury due to interindividual variability in pharmacokinetics. Poster presented at Society of Toxicology 37th Annual Meeting, Seattle, WA, March 1998.
1997 (1 POST)
Evaluating pharmacokinetics and pharmacodynamics for noncancer effects from trichloroethylene (TCE)
Covington TR, Barton HA, Clewell HJ III. Evaluating pharmacokinetics and pharmacodynamics for noncancer effects from trichloroethylene (TCE). Poster presented at Society of Toxicology 36th Annual Meeting, Cincinnati, OH, March 1997.
1996 (1 POST)
Developing physiologically-based pharmacokinetic (PB-PK) models for manganese and iron
Covington TR, Clewell HJ III, Gearhart JM, Andersen ME. Developing physiologically-based pharmacokinetic (PB-PK) models for manganese and iron. Poster presented at the Society of Toxicology Annual Meeting, Anaheim, CA, March 1996.